GE Healthcare and Johnson & Johnson's Janssen Pharmaceutica N.V. Deal Pairs Two Alzheimer's Powerhouses

Medical News Today -- GE Healthcare announced a research agreement to collaborate with Janssen Pharmaceutica NV, L.L.C. (Janssen) to identify a biosignature related to Alzheimer's disease. This research effort will combine expertise in data integration, informatics, genomics and imaging. Its goal will be to find a biosignature that may enable the detection of Alzheimer's disease before the onset of clinical symptoms. The collaboration is part of a broad portfolio of diagnostic solutions that GE Healthcare is developing in the Alzheimer's field.